CA
IBRX icon

CoreCap Advisors’s ImmunityBio IBRX Stock Holding History

CoreCap Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$217 Hold
23
– – ﹤0.01% 2944
2026
Q2 		$201 Hold
23
– – ﹤0.01% 3006
2026
Q1 		$176 Buy
+23
New +$157 ﹤0.01% 2773
2025
Q1 		– Sell
-70
Closed -$179 – 3217
2024
Q4 		$179 Buy
+70
New +$292 ﹤0.01% 2732

Other funds holding IBRX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
MWM
MFG Wealth Management Indianapolis, Indiana $138M AUM 31.54% 1-Year Est. Return
CFO
Collective Family Office York, Pennsylvania $484M AUM 13.93% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $532M AUM 15.78% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $546M AUM 14.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return
FWP
Firethorn Wealth Partners Augusta, Georgia $313M AUM 15.55% 1-Year Est. Return

CoreCap Advisors's IBRX Position: Q3 2026 in Review

CoreCap Advisors held its ImmunityBio (IBRX) position steady in Q3 2026 at 23 shares worth $217. The position accounts for ﹤0.01% of the portfolio, ranked #2944.

CoreCap Advisors first reported a position in IBRX in Q4 2024 and has held it in 4 quarters since. 27 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • CoreCap Advisors held 23 shares of ImmunityBio worth $217 as of Q3 2026.
  • CoreCap Advisors left its ImmunityBio share count unchanged in Q3 2026.
  • ImmunityBio made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2944 holding.
  • CoreCap Advisors first reported a position in ImmunityBio in Q4 2024 and has held it in 4 quarters since.
  • 27 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.